# ALK in T-cell lymphoma

1 EU-approved indication in T-cell lymphoma needs a ALK result: crizotinib (2nd line).

## Approved indications

### ALK fusion

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Crizotinib](https://oncolabels.com/drugs/crizotinib) (Xalkori) | ALK fusion | Monotherapy | 2nd line | Systemic ALCL only; Children and adolescents only; Relapsed or refractory; Age ≥ 1 to < 18 years |

## Label wording

- **Crizotinib** (Xalkori), T-cell lymphoma, 2nd line: “The treatment of paediatric patients (age ≥1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)” [SmPC](https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/t-cell-lymphoma/alk